These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29518282)

  • 41. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
    Kantarci K; Reynolds G; Petersen RC; Boeve BF; Knopman DS; Edland SD; Smith GE; Ivnik RJ; Tangalos EG; Jack CR
    AJNR Am J Neuroradiol; 2003 May; 24(5):843-9. PubMed ID: 12748083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
    Kantarci K; Lowe VJ; Boeve BF; Senjem ML; Tosakulwong N; Lesnick TG; Spychalla AJ; Gunter JL; Fields JA; Graff-Radford J; Ferman TJ; Jones DT; Murray ME; Knopman DS; Jack CR; Petersen RC
    Ann Neurol; 2017 Jan; 81(1):58-67. PubMed ID: 27863444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
    Waldman AD; Rai GS
    Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cerebral metabolism in patients with cognitive disorders: a combined MRS and PET study].
    Khomenko YG; Kataeva GV; Bogdan AA; Chernysheva EM; Susin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(1):51-58. PubMed ID: 30778031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Franzmeier N; Duering M; Weiner M; Dichgans M; Ewers M;
    Neurology; 2017 Mar; 88(11):1054-1061. PubMed ID: 28188306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.
    Fu L; Liu L; Zhang J; Xu B; Fan Y; Tian J
    Eur Radiol; 2014 Nov; 24(11):2800-9. PubMed ID: 25097125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.
    Murray ME; Przybelski SA; Lesnick TG; Liesinger AM; Spychalla A; Zhang B; Gunter JL; Parisi JE; Boeve BF; Knopman DS; Petersen RC; Jack CR; Dickson DW; Kantarci K
    J Neurosci; 2014 Dec; 34(49):16247-55. PubMed ID: 25471565
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Nedelska Z; Przybelski SA; Lesnick TG; Schwarz CG; Lowe VJ; Machulda MM; Kremers WK; Mielke MM; Roberts RO; Boeve BF; Knopman DS; Petersen RC; Jack CR; Kantarci K
    Neurology; 2017 Sep; 89(13):1391-1399. PubMed ID: 28842444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
    Tolboom N; van der Flier WM; Yaqub M; Koene T; Boellaard R; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    Neurology; 2009 Dec; 73(24):2079-85. PubMed ID: 20018636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study.
    Voevodskaya O; Poulakis K; Sundgren P; van Westen D; Palmqvist S; Wahlund LO; Stomrud E; Hansson O; Westman E;
    Neurology; 2019 Jan; 92(5):e395-e405. PubMed ID: 30610093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
    García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
    Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.